|
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Clinical research trials and Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer. Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer  Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
For Condition: peritoneal cavity cancer,recurrent ovarian epithelial cancer
Status: No longer recruiting
Sponsor(s): Beth Israel Deaconess Medical Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating women who have ovarian epithelial cancer or primary peritoneal cancer that has not responded to previous treatment.
Details: OBJECTIVES: - Determine the activity of docetaxel in women with platinum resistant, refractory ovarian epithelial or primary peritoneal serous cancer. OUTLINE: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive a minimum of 6 courses of therapy, including 2 courses beyond CR. PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial or primary peritoneal serous cancer that is resistant to platinum therapy - Platinum resistance as defined by one of the following: - Relapse within 6 months of platinum based chemotherapy - Residual disease after completion of platinum based chemotherapy - Disease progression while receiving platinum based chemotherapy - Marker only relapse (CA-125 elevation) and measurable disease - Bidimensionally measurable disease on exam or CT scan PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Female Performance status: - ECOG 0-2 Life expectancy: - Greater than 2 months Hematopoietic: - WBC at least 3,000/mm3 - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin no greater than upper limit of normal (ULN) - SGPT or SGOT no greater than 1.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN Renal: - Creatinine no greater than 1.5 mg/dL Cardiovascular: - Acceptable cardiac exam - No active cardiac ischemia Pulmonary: - Acceptable pulmonary exam - No active pulmonary infection or compromise Other: - Not pregnant or nursing - No severe peripheral neuropathy (grade 2 or greater) - No other significant psychiatric or medical conditions that would interfere with compliance - No other malignancies within the past 3 years, except: - Limited basal or squamous cell skin cancer - Carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior cytokine therapy Chemotherapy: - See Disease Characteristics - At least 3 weeks since prior chemotherapy for ovarian epithelial or peritoneal serous cancer - Prior paclitaxel allowed - No prior docetaxel - At least 3 years since prior chemotherapy for other disease Endocrine therapy: - Not specified Radiotherapy: - No prior pelvic radiotherapy Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
StephenCannistra, Study Chair, Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: CDR0000067292; BIH-99-1286,NCI-V99-1565
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004081
Other Peritoneal Cavity Cancer Studies:
1. Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
2. TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
3. BMS-247550 in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
4. UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
5. Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Related Studies:
Other peritoneal cavity cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
|
|
|
|
|
|
|
|
